银诺医药二次赴港IPO:一款减肥药可否撑起46亿估值

中国基金报
Aug 14

【导读】银诺医药二次赴港IPO:一款减肥药可否撑起46亿估值?见习记者荧墨今年初,一款被称为“国产司美格鲁肽”的糖尿病新药高调上市,它是国内首个拥有自主知识产权的人源超长效GLP-1(胰高血糖素样肽-1)药物依苏帕格鲁肽α(商品名:怡诺轻)。而怡诺轻的获批上市,也结束了广州银诺医药集团股份有限公司(下称银诺医药)自成立起连续十年零收入的状态。凭借超长半衰期及低价策略,怡诺轻迅速打入市场。...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10